CTOs on the Move

Encoded Therapeutics

www.encoded.com

 
Encoded Therapeutics Inc. is a biotechnology company advancing precision medicines for a broad range of genetic disorders. Our mission is to unlock new opportunities for viral gene therapy through genomics-driven discovery. We focus on delivering life-changing advances for individuals with genetic disorders not addressable with current approaches.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.encoded.com
  • 341 Oyster Point Blvd.
    South San Francisco, CA USA 94080
  • Phone: 650.491.0272

Executives

Name Title Contact Details
Martin Moorhead
Chief Technology Officer Profile

Funding

Encoded Therapeutics raised $135M on 07/22/2020

Similar Companies

Argenx

The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.

Celularity

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity`s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature`s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Chiropractors Buying Group

Chiropractors Buying Group is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perimeter Resources

Perimeter Resources is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.